Molecular Mechanisms for Individualized Cancer Care

Journal of the American College of Surgeons

Volumn 207, Issue 2, 2008, Pages 250-258

  Mansour, John C ^a   Schwarz, Roderich E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; ANTIESTROGEN; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; OXALIPLATIN; ROSCOVITINE; SUNITINIB; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG SENSITIVITY; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMICS; GYNECOLOGIC CANCER; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR MECHANICS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOLOGY; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK ASSESSMENT; STOMACH CANCER; SURGICAL RISK; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOADJUVANT THERAPY; NEOPLASMS; PATIENT CARE PLANNING; PROGNOSIS; PROTEOMICS;

EID: 48949116110     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2008.03.003     Document Type: Review

References (64)

1. Scherf U., Ross D.T., Waltham M., et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 24 (2000) 236-244
2. McGuire W.L., Chamness G.C., and Fuqua S.A. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5 (1991) 1571-1577
3. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281 (1999) 2189-2197
4. Chlebowski R.T., Col N., Winer E.P., et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20 (2002) 3328-3343
5. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 61 (2001) 1-13
6. Gianni L. Future directions of paclitaxel-based therapy of breast cancer. Semin Oncol 24 (1997) S17-91-S17-96
7. Gusterson B.A., Gelber R.D., Goldhirsch A., et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10 (1992) 1049-1056
8. Drebin J.A., Link V.C., Stern D.F., et al. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41 (1985) 697-706
9. Shepard H.M., Lewis G.D., Sarup J.C., et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11 (1991) 117-127
10. Hortobagyi G.N. Trastuzumab in the treatment of breast cancer. N Engl J Med 353 (2005) 1734-1736
11. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
12. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
13. Potti A., Dressman H.K., Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 12 (2006) 1294-1300
14. Chang J.C., Wooten E.C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
15. Pittman J., Huang E., Dressman H., et al. Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci USA 101 (2004) 8431-8436
16. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
17. Cheng S.H., Horng C.F., West M., et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 24 (2006) 4594-4602
18. Gazdar A.F., Miyajima K., Reddy J., et al. Molecular targets for cancer therapy and prevention. Chest 125 (2004) 97S-101S
19. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
20. Arteaga C.L. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284 (2003) 122-130
21. Sunaga N., Tomizawa Y., Yanagitani N., et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 56 (2007) 383-389
22. Sekine I., Minna J.D., Nishio K., et al. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. J Thorac Oncol 1 (2006) 31-37
23. Kawasaki M., Nakanishi Y., Kuwano K., et al. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 34 (1998) 1352-1357
24. Metzger R., Leichman C.G., Danenberg K.D., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 (1998) 309-316
25. Dabholkar M., Vionnet J., Bostick-Bruton F., et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94 (1994) 703-708
26. Cobo M., Isla D., Massuti B., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25 (2007) 2747-2754
27. Nakajima Y., Miyake S., Nagai K., et al. CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein. Jpn J Cancer Res 92 (2001) 1335-1341
28. Nakajima Y., Miyake S., Tanaka K., et al. The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11. Cancer Sci 95 (2004) 464-468
29. Luthra R., Luthra M.G., Izzo J., et al. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol 33 (2006) S2-S5
30. Hayashida Y., Honda K., Osaka Y., et al. Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin Cancer Res 11 (2005) 8042-8047
31. DeMatteo R.P., Maki R.G., Singer S., et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245 (2007) 347-352
32. Mauro M.J., and Druker B.J. STI571: targeting BCR-ABL as therapy for CML. Oncologist 6 (2001) 233-238
33. Andersson J., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology (2006) 1301573-1301581
34. Lasota J., Vel Dobosz A.J., Wasag B., et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest 87 (2007) 1029-1041
35. Wardelmann E., Buttner R., Merkelbach-Bruse S., and Schildhaus H.U. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 451 (2007) 743-749
36. Joensuu H. Second line therapies for the treatment of gastrointestinal stromal tumor. Curr Opin Oncol 19 (2007) 353-358
37. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11 (2005) 4182-4190
38. Miselli F.C., Casieri P., Negri T., et al. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Clin Cancer Res 13 (2007) 2369-2377
39. Sleijfer S., Wiemer E., Seynaeve C., and Verweij J. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist 12 (2007) 719-726
40. Xiong H.Q., and Abbruzzese J.L. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29 (2002) 31-37
41. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
42. Allegra C.J., Paik S., Colangelo L.H., et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study J Clin Oncol 21 (2003) 241-250
43. Aschele C., Debernardis D., Bandelloni R., et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Ann Oncol 13 (2002) 1882-1892
44. Berglund A., Edler D., Molin D., et al. Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma. Anticancer Res 22 (2002) 3653-3659
45. Johnston P.G., Benson III A.B., Catalano P., et al. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 21 (2003) 815-819
46. Saito H., Tsujitani S., Oka S., et al. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer 81 (1999) 484-489
47. Mariadason J.M., Arango D., Shi Q., et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63 (2003) 8791-8812
48. Arango D., Wilson A.J., Shi Q., et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91 (2004) 1931-1946
49. Eschrich S., Yang I., Bloom G., et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23 (2005) 3526-3535
50. Heintz A.P., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. J Epidemiol Biostat 6 (2001) 107-138
51. Petignat P., du Bois A., Bruchim I., et al. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?. Crit Rev Oncol Hematol 62 (2007) 137-147
52. Hartmann L.C., Lu K.H., Linette G.P., et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11 (2005) 2149-2155
53. Crijns A.P., Gerbens F., Plantinga A.E., et al. A biological question and a balanced (orthogonal) design: the ingredients to efficiently analyze two-color microarrays with Confirmatory Factor Analysis. BMC Genomics 7 (2006) 232
54. Berchuck A., Iversen E.S., Lancaster J.M., et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11 (2005) 3686-3696
55. Spentzos D., Levine D.A., Kolia S., et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23 (2005) 7911-7918
56. Dressman H.K., Berchuck A., Chan G., et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25 (2007) 517-525
57. Metzger R., Danenberg K., Leichman C.G., et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4 (1998) 2371-2376
58. Chow L.Q., and Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25 (2007) 884-896
59. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
60. Bogner V., Kirchhoff C., Baker H.V., et al. Gene expression profiles are influenced by ISS, MOF, and clinical outcome in multiple injured patients: a genome-wide comparative analysis Langenbecks Arch Surg 392 (2007) 255-265
61. Cobb J.P., Brownstein B.H., Watson M.A., et al. Injury in the era of genomics. Shock 15 (2001) 165-170
62. Canter J.A., Norris P.R., Moore J.H., et al. Specific polymorphic variation in the mitochondrial genome and increased in-hospital mortality after severe trauma. Ann Surg 246 (2007) 406-414
63. Feezor R.J., Baker H.V., Xiao W., et al. Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair. J Immunol 172 (2004) 7103-7109
64. Habel L.A., Shak S., Jacobs M.K., et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8 (2006) R25